We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Genzyme Corp. - Genzyme Corp. Common Stock (MM) | NASDAQ:GENZ | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 76.25 | 0 | 00:00:00 |
From Jan 2020 to Jan 2025
DOW JONES NEWSWIRES
BlackRock Inc. (BLK) is slated to replace Genzyme Corp. (GENZ) in the S&P 500 index as the biotechnology company is set to be acquired, Standard & Poor's said Tuesday.
Shares of BlackRock, the world's biggest money manager, rose 5.5% to $4.91 after hours. As of the close, the stock had risen 44% in the past year.
Shares of companies joining the S&P 500 often rise because many portfolio managers try to track the index. To do that, they must buy shares of the companies that become part of it.
The shift in the index is scheduled to occur after the close of trading on Friday. Genzyme is slated to be bought by Sanofi-Aventis SA (SNY) for $20.1 billion plus a contingent value right.
BlackRock in January reported its fourth-quarter profit more than doubled thanks largely to improving equity markets and higher performance fees.
-By Nathan Becker, Dow Jones Newswires; 212-416-2855; nathan.becker@dowjones.com
1 Year Genzyme Chart |
1 Month Genzyme Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
